Form 4: Terns Pharmaceuticals Director Jill M. Quigley Acquires 32,000 Stock Options
SEC Form 4
Director Jill M. Quigley reports acquisition of 32,000 stock options in Terns Pharmaceuticals.
Summary
- Jill M. Quigley, a director of Terns Pharmaceuticals, acquired 32,000 stock options on June 10, 2024.
- The options have an exercise price of $6.99.
- The options vest on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting following the grant date.
- The options expire on June 9, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of transaction: Jill M. Quigley acquired 32,000 stock options. |
| 06/09/2034 | Expiration date of the stock options. |
| 06/14/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.